Intraarterial Delivery of Adenovirus Vectors and Liposome-DNA Complexes to Experimental Brain Neoplasms
- 20 January 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (2) , 311-318
- https://doi.org/10.1089/10430349950019093
Abstract
This study investigated the intraarterial delivery of genetically engineered replication-deficient adenovirus vectors (AVs) and cationic liposome-plasmid DNA complexes (lipoDNA) to experimental brain tumors. Adenovirus or lipoDNA was injected into the internal carotid artery (ICA) of F344 rats harboring intracerebral 9L gliosarcomas, using bradykinin (BK) to selectively permeabilize the blood-tumor barrier (BTB). Brain and internal organs of the animals were collected 48 hr after vector injection and stained for expression of the marker gene product, beta-galactosidase (beta-Gal). Intracarotid delivery of AV to 9L rat gliosarcoma without BTB disruption resulted in transgene expression in 3-10% of tumor cells distributed throughout the tumor. Virus-mediated expression of beta-gal gene products in this tumor model was particularly high in small foci ( 0.5 mm), which had invaded the normal brain tissue surrounding the main tumor mass. In these foci more than 50% of tumor cells were transduced. BK infusion increased the amount of transgene-expressing cells in larger tumor foci to 15-30%. In the brain parenchyma only a few endothelial cells expressed beta-gal owing to AV-mediated gene transfer. Intracarotid delivery of lipoDNA bearing a cytoplasmic expression cassette rendered more than 30% of the tumor cells positive for the marker gene without BTB disruption. The pattern of distribution was in general homogeneous throughout the tumor. BK infusion was able to increase further the number of transduced tumor cells to more than 50%. Although lipoDNA-mediated gene transfer showed increased efficacy as compared with AV-mediated gene transfer, it had less specificity since a larger number of endothelial and glial cells also expressed the transgene. AV and lipoDNA injections, in the absence and presence of BK, also resulted in transduction of peripheral organs. AV showed its known predilection for liver and lung. In the case of lipoDNA, parenchymal organs such as liver, lung, testes, lymphatic nodes, and especially spleen, were transduced. These findings indicate that intracarotid application of AV and lipoDNA vectors can effectively transduce tumor cells in the brain, and that BTB modulation by BK infusion can further increase the number of transgene-expressing tumor cells.Keywords
This publication has 31 references indexed in Scilit:
- Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumorsGene Therapy, 1998
- Unlocking the Blood–Brain Barrier: A Role for RMP-7 in Brain Tumor TherapyExperimental Neurology, 1996
- Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir TreatmentHuman Gene Therapy, 1996
- Treatment of Advanced CNS Malignancies with the Recombinant Adenovirus H5.010RSVTK: A Phase I Trial. University of Pennsylvania Medical Center, PhiladelphiaHuman Gene Therapy, 1996
- Selective Uptake of Viral and Monocrystalline Particles Delivered Intra-Arterially to Experimental Brain NeoplasmsHuman Gene Therapy, 1995
- Gene Expression from Recombinant Viral Vectors in the Central Nervous System after Blood-Brain Barrier DisruptionNeurosurgery, 1995
- Adenovirus‐mediated gene therapy of experimental gliomasJournal of Neuroscience Research, 1994
- Gene Transfer into Experimental Brain Tumors Mediated by Adenovirus, Herpes Simplex Virus, and Retrovirus VectorsHuman Gene Therapy, 1994
- Cloning and pharmacological characterization of a human bradykinin (BK-2) receptorBiochemical and Biophysical Research Communications, 1992
- Liposomes for the transformation of eukaryotic cellsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1991